Table 1. EGFR monoclonal antibodies in HNSCC clinical trials.

Agent	Phas e	Stage	Therapy	Reference	Uniquenes s of Agent/Stu dy
Cetuximab	I	Advanced solid tumors	Cetuximab plus bortezomib (proteasome inhibitor)	[97]	Preclinical data suggests enhanced effect of combining these two agents
Cetuximab	II	Recurrent/Metast atic	Cetuximab + BIBW2992 (ErbB2 TKI)	ClinicalTrials.gov NCT00514943	Comparing C225 vs. TKI in platinum refractory patient
Cetuximab	III	Recurrent/Metast atic	Cisplatin vs. Cisplatin plus cetuximab	[50]	Prior clinical efficacy shown in combined therapy
Cetuximab	II	Resectable Stage III/IV	Cetuximab plus carboplatin, placlitaxel	[98]
Cetuximab	II	Stage III/IV	Cetuximab plus cisplatin/docetaxe l plus radiation	ClinicalTrials.gov NCT00084318
Cetuximab	II	Stage III/IV	Cetuximab plus radiation and chemotherapy	ClinicalTrials.gov NCT00646659
Hu-Max (Zalitumum ab)	I/II	Recurrent/Metast atic	Monotherapy	ClinicalTrials.gov NCT00093041	Possible antineiplast ic and ADCC mechanism s demonstrat ed by the antibody Zalitumum ab
Nimotuzum ab	II	Localy Advanced	Nimotuzumab plus cisplatin/radiothe rapy	ClinicalTrials.gov NCT00702481	Nimotuzu mab demonstrat es unique heavy chain sequences and exhibits a good safety profile
Panitumum ab	I	Locally Advanced HNSCC	Panitumumab plus induction chemotherapy	[99]	Has shown promice in metastatic colorectal cancer
Cetuximab and Erlotinib	I/II	Advanced (Phase I)	Cetuximab plus erlotinib	ClinicalTrials.gov NCT00397384
Cetuximab	III	Stage III/IV	Cetuximab plus Radiotherapy vs radiotherapy alone	[100]